Don't leave them on the lab bench while you answer emails or grab coffee
No fad diets, just real results
Tirzepatide (Mounjaro): A dual GIP/GLP-1 receptor agonist with MHRA approval for type 2 diabetes and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
Finally, we outline the implications of adopting semaglutide as a disease-modifying agent in MASH with F2-F3 fibrosis, note the study limitations and remaining questions, and argue that combinatorial approaches targeting complementary metabolic and hepatocentric pathways may define the next phase of MASLD management
In June, Novo Nordisk ended its partnership with Hims & Hers, which had been announced just two months earlier, accusing the online marketplace of deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk. Shares of Wegovy manufacturer Novo Nordisk dropped more than 8% on Thursday to close at $43.34 Shares of Hims & Hers popped around 20% in pre-market trading following the announcement, but fell steadily throughout the day to close down 3.8% at $23.48 before falling another 1% in after-hours